Deciquan Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a micronized decoquinate active pharmaceutical ingredient supplied for further manufacture into medicated feeds, oral solid dosage forms, oral suspensions, and sterile veterinary preparations where the regulatory dossier supports such use. The active species is ethyl 6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylate, CAS 18507-89-6, molecular formula C₂₄H₃₅NO₅, molecular weight 417.54 g/mol. The product is classified as a synthetic quinolone coccidiostat, not an ionophore antibiotic. Pharmacodynamic action occurs through inhibition of mitochondrial cytochrome bc₁ complex at the ubiquinone site in apicomplexan parasites, interrupting sporozoite and merozoite electron transport without binding to mammalian sodium or calcium channel targets associated with polyether ionophore toxicity. The product name “Solution” denotes the grade intended for incorporation into solution and suspension formulations, not a finished liquid dosage form. The physical form is a pale yellow to off-white crystalline powder released under a veterinary API specification; it is not dispensed as a finished therapeutic product.

Compendial Purity and Particle-Size Boundaries

Release documentation for the micronized grade is aligned with current pharmacopoeial monographs for decoquinate where applicable. The typical assay range is 98.0% to 102.0% on the dried basis, with loss on drying not more than 0.5% determined at 105°C for 2 h, residue on ignition not more than 0.1%, and total related substances not more than 1.0%. Residual solvents are controlled according to USP <467> or Ph. Eur. 2.4.24. Heavy metals are reported only where a specific dossier requires the older general chapter; where applicable, acceptance is not more than 20 ppm. The API is air-jet milled for the tablets/capsules/solutions grade; laser diffraction per ISO 13320-1:2020 commonly reports 90% of the volume distribution at or below 45 µm and 100% at or below 150 µm. The fine particle size improves content uniformity but lowers bulk density and increases electrostatic adhesion; manufacturers must evaluate flow properties before selecting direct compression.

What Limits Aqueous Processability in This API?

Decoquinate is practically insoluble in water; the lipophilic decyloxy side chain and the 4-hydroxyquinoline core produce a strong preference for chlorinated solvents and limited solubility in ethanol. This property is the primary constraint governing liquid and parenteral forms. Finished solutions for oral drench or drinking-water application are therefore formulated as suspensions, co-solvent solutions, or microemulsions, not as simple aqueous solutions. For injectable products, a fully aqueous solution is not generally achievable without co-solvent concentrations that may exceed acceptable veterinary solvent limits; published data for a ready-to-use aqueous injectable decoquinate solution is limited. Sterile suspension presentation requires particle-size control in the low micrometer range, aseptic wetting with a non-ionic surfactant such as polysorbate 80 at 0.1%–0.5% w/v, and terminal heat or filtration validation appropriate to the formulation. Physicochemical stability of decoquinate in acidic aqueous media may be limited by hydrolysis of the ester side chain; the pH range of oral liquid vehicles is typically maintained between 4.0 and 7.0 when an aqueous suspension is used. These constraints must be addressed during formulation development because they differ from the freely water-soluble amprolium hydrochloride or the more lipophilic ionophore carriers.

Wet granulation is the preferred manufacturing route for decoquinate tablets and capsules because direct compression often produces segregation and content uniformity failure from the API’s low bulk density and electrostatic adhesion. A standard high-shear granulation process uses purified water or a binder solution of povidone K30 at 2%–5% w/w; the wet mass is dried to a loss-on-drying endpoint of 2.0%–4.0% and passed through a 1.0 mm oscillating granulator. Content uniformity is evaluated according to USP <905> or Ph. Eur. 2.9.40. Tablet specifications for immediate-release veterinary products commonly require hardness 6–10 kp, friability not more than 1.0%, and disintegration not more than 15 min in purified water at 37°C. Capsule blends are prepared by geometric dilution into lactose monohydrate or maize starch; decoquinate is added late in the blending sequence to reduce electrostatic loss to bin surfaces. Blend uniformity is assessed according to current regulatory guidance using at least 10 stratified samples; a relative standard deviation below 5.0% is generally expected before compression or encapsulation. Tablet and capsule development should include ribbon or slugging trials only if the API is pre-granulated with a high-shear granulator; otherwise the cohesive fines may cause poor die fill and weight variation.

When a Premix Line Must Handle Low-Dose Coccidiostat

Feed premix and granule manufacture for decoquinate requires stepwise dilution into a dry carrier matrix because the target final feed concentration is often low. Carriers include ground limestone, defatted rice hulls, corn cob fractions, or maltodextrin-based agglomerates; selection is based on oil adsorption capacity, bulk density, and electrostatic interaction with the micronized API. Premix homogeneity is verified using the decoquinate assay procedure from the current pharmacopoeial monograph or a validated HPLC method, with 10 incremental samples taken across the blender discharge. The acceptance criterion is normally a coefficient of variation below 5%. Dry mixing should avoid excessive heat and shear; the crystalline decoquinate is stable under normal pelleting conditions, but maintenance of particle size during mixing is critical. Fluid-bed granulation of medicated granules requires control of inlet air temperature in the range 60°C–70°C and outlet air temperature below 45°C, with spray rate adjusted to maintain a granule moisture content of 2%–4%. Bags and bins should be deionized or grounded where static charge causes API migration; “premix dust-off” is a recognized batch-to-batch loss variable in feed mills. These process parameters are less demanding than for ionophore premixes because decoquinate has no electrostatic incompatibility with bentonite or hydrated sodium calcium aluminosilicate carriers, but washout verification is still required when a line switches from ionophore-free to coccidiostat-containing feed.

The solutions presentation for this API is generally a stabilized oral suspension or an oily injectable suspension rather than a true aqueous solution. In oral suspensions, decoquinate is dispersed in a structured vehicle containing microcrystalline cellulose and carboxymethylcellulose sodium to retard sedimentation; viscosity may be adjusted with xanthan gum. Preservation systems are selected to avoid ester hydrolysis; if paraben esters are used, the pH is maintained in the neutral range to minimize degradation. A “shake well before use” label and syringability testing are mandatory. For injection, particle-size reduction to the sub-10 µm range and sterilisation by gamma irradiation or aseptic processing are required; filtration of a suspension is not feasible because the active is not in solution. Syringeability and injectability are controlled by particle size distribution, vehicle viscosity, and needle gauge; an 18–21 G needle is commonly used for evaluation if the formulation is intended for subcutaneous or intramuscular administration in cattle. Published data for this specific configuration is limited, and product developers should conduct target animal safety studies under the relevant veterinary regulatory framework.

Why Decoquinate Is Not an Ionophore and Does Not Share Equine Toxicity

Decoquinate differs from polyether ionophore coccidiostats in both mechanism and safety. Ionophores such as monensin, lasalocid, narasin, and salinomycin act by shuttling cations across cell membranes, creating toxic ion flux in equine muscle and other sensitive tissues. Decoquinate inhibits mitochondrial Complex III in apicomplexan parasites and has very low mammalian systemic absorption, which is reflected in a wide margin of safety in cattle, sheep, and poultry. It is not a known equine hazard and may be used in equine feed under specific regulatory conditions in some jurisdictions. The compatibility profile is also different: ionophore antibiotics are contraindicated with tiamulin and certain macrolide antibiotics because of cytochrome P450 inhibition leading to ionophore accumulation; decoquinate does not share this interaction. Compared with triazines such as toltrazuril and diclazuril, decoquinate is primarily prophylactic and lumenal. Triazines are often used for treatment of clinical coccidiosis and have greater systemic distribution. Decoquinate is therefore not a direct substitute for toltrazuril in an outbreak where deep-tissue schizonts are already established. Compared with amprolium, which is a thiamine antagonist, decoquinate does not interfere with vitamin B₁ metabolism in cattle and is not associated with polioencephalomalacia. These differences determine selection in formulatory and regulatory dossiers.

Analytical method transfer should include assay precision at the target feed concentration because matrix interferences from alfalfa meal, calcium carbonate, and trace mineral premixes can suppress decoquinate recovery in some HPLC conditions. Extraction with acidified methanol or acetonitrile followed by cleanup on a reversed-phase cartridge is standard; detection is typically by ultraviolet absorption, and laboratories should confirm wavelength specificity against the reference standard. Method validation should follow ICH Q2(R1) for assay specificity, linearity, accuracy, and precision, and the low feed concentrations require a limit of quantification below the expected target inclusion. Release testing for the pure API and finished premix should be documented under the applicable veterinary master file or marketing authorization, with retention samples stored in moisture-resistant containers to prevent particle aggregation and static drift.